Ibio Inc IBIO

Healthcare Biotechnology

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

NYSEAM:IBIO - Post by User

Ibio Inc

<< Previous

Bullboard Posts

Next >>

Post by Patienceiskeeon Sep 28, 2020 10:52pm

134 Views

Post# 31633516

We definitely need a vaccine in North America five

With the changing weather in the upcoming holidays in the u.s. and Canada things might get heated up over here quick. I ran into a very knowledgeable person the other day while flying told me I should sell Inovio Pharmaceuticals when it was at $17 and Buy in over here. Went on to say i b i o is definitely going to go to the next phase without any problems. Sometimes I just with the rumours. Hell I ain't no scientist

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages